{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:10:12Z","timestamp":1776384612804,"version":"3.51.2"},"reference-count":26,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiology"],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Objectives:&lt;\/i&gt;&lt;\/b&gt; To evaluate the efficacy and safety of icosabutate, an oral, once-daily, first-in-class medication, in reducing non-high-density lipoprotein cholesterol (non-HDL-C) in patients with persistent hypertriglyceridemia despite statin therapy. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; The study was designed to randomly assign 140 patients with fasting triglyceride levels \u2265200 but &lt;500 mg\/dl on a stable dose of statin therapy to receive either masked icosabutate 600 mg once daily or a control for 12 weeks. The primary end point was a percentage change in non-HDL-C from baseline to 12 weeks. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; With icosabutate, non-HDL-C levels were reduced (-9.2%) when compared with the control (-0.4%) for a between-group difference of -7.4% (p = 0.02). Compared with the control, icosabutate reduced triglycerides (-27.0%, p &lt; 0.001), very- low-density lipoprotein (VLDL) cholesterol (-31.5%, p &lt; 0.001) and apolipoprotein C-III (-22.5%, p &lt; 0.001). LDL-C levels did not change (0.5%, p = 0.87). HDL-C (10.2%, p &lt; 0.001) was increased. After 113 subjects had been randomized, the study was terminated due to a partial clinical hold imposed by US regulators after observing QT prolongation at supratherapeutic doses of icosabutate in a dog study. In this study, adverse events were balanced between treatment arms, and there were no discontinuations due to adverse events. &lt;b&gt;&lt;i&gt;Conclusions:&lt;\/i&gt;&lt;\/b&gt; Icosabutate was efficacious in lowering non-HDL-C and other biomarkers of cardiovascular risk and was generally well tolerated.<\/jats:p>","DOI":"10.1159\/000445047","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T21:04:41Z","timestamp":1462309481000},"page":"3-12","source":"Crossref","is-referenced-by-count":14,"title":["Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia"],"prefix":"10.1159","volume":"135","author":[{"given":"John J.P.","family":"Kastelein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Hall\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runar","family":"Vige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svein Olaf","family":"Hustvedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Orloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold E.","family":"Bays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2016,5,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61177-6"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.10.038"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.03.544"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.04.008"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2012.04.003"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001282"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1543"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60545-4"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.08.1026"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.11.008"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.111.226100"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.10.012"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00530-7"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.03.037"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/hc3501.095214"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307095"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308027"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.07.420"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.07.018"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.08.027"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.02.036"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-014-0090-3"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2013.10.003"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400284"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/174182679700400511"}],"container-title":["Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/445047","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/445047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:53:18Z","timestamp":1745430798000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000445047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,8,16]]}},"URL":"https:\/\/doi.org\/10.1159\/000445047","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.5129680","asserted-by":"subject"}]},"ISSN":["0008-6312","1421-9751"],"issn-type":[{"value":"0008-6312","type":"print"},{"value":"1421-9751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}